You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.


Clinical Pearls & Compelling Evidence for Internists: Integrating Guidelines to Optimize Cardiorenal Outcomes in T2D

  • Authors: Rajiv Agarwal, MD, MS (Co-Chair); Janet B. McGill, MD, MA; Joseph A. Vassalotti, MD (Co-Chair)
  • CME Released: 6/23/2023
  • Valid for credit through: 6/23/2024, 11:59 PM EST
Start Activity

  • Credits Available

    Physicians - maximum of 1.00 AMA PRA Category 1 Credit(s)™

    You Are Eligible For

    • Letter of Completion

Target Audience and Goal Statement

Primary Care Physicians, Nephrologists, Cardiologists, Endocrinologists/Diabetologists, Physician Assistants/Nurse Practitioners, Nurses Specialists.

Internal medicine specialists are at the forefront of patient care and play a critical role in detecting CKD and preventing disease progression in patients with T2D, particularly in the early stages of the disease. With recent updated guidelines reflecting studies demonstrating substantial improvements in cardiorenal outcomes with use of novel agents, clinicians have an even greater opportunity to optimize T2D management in CKD. Join the respected investigators and guideline experts as they share clinical pearls and compelling evidence to facilitate integration of screening approaches, updated guidelines and recent advances to optimize cardiorenal outcomes.

Upon completion of this activity, participants will:

  1. Assess evidence-based data supporting recent additions and updates to clinical practice guidelines in patients with CKD and T2D
  2. Explain screening approaches beyond conventional EGFR, including the presence of albuminuria as an important cardiorenal risk marker in high-risk individuals
  3. Recognize that residual cardiorenal risk exists with standard-of-care treatments and that targeting alternate pathways may fill unmet needs by addressing drivers of inflammation and fibrosis, often overlooked in CKD
  4. Describe patient risk profiles, along with clinical and tolerability considerations, that will help identify those who will derive most benefit using agents with demonstrated cardiorenal benefit


Letters & Sciences and PACE require planners, faculty, and others who are in a position to control the content of this activity to disclose all financial relationships they may have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to the providers' policies. Letters & Sciences and PACE are committed to providing learners with high-quality accredited CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty have agreed to disclose any unlabeled/unapproved uses of drugs or products in his or her presentations.


  • Rajiv Agarwal, MD, MS (Co-Chair)

    Professor of Medicine
    Indiana University School of Medicine
    Nephrology Specialist
    Richard Roudebush VA Medical Center
    Indianapolis, Indiana


    Served as consultant for Bayer Pharmaceuticals; Boehringer Ingelheim; Vifor Pharma; Diamedica
    Served on the Data Safety Monitoring Board for Chinook; Vertex
    Received royalties from UptoDate

  • Joseph A. Vassalotti, MD (Co-Chair)

    Clinical Professor
    Icahn School of Medicine at Mount Sinai
    New York, New York


    Served as consultant for AstraZeneca, Inc., Renalytix PLC


  • Janet B. McGill, MD, MA

    Professor of Medicine, Division of Endocrinology, Metabolism and Lipid Research
    Center for Advanced Medicine
    Washington University in St. Louis
    St. Louis, Missouri


    Served as an advisor or consultant for: Bayer; Boehringer Ingelheim; Dexcom; Gilead; Mannkind; PreventionBio
    Received grants for clinical research support from: Medtronic; National Institutes of Health; Novo Nordisk

Executive Committee, CME Committee, Planning Committee, Curriculum Committee Members

Content managers/members of the CME, planning, executive, and curriculum committees of Letters & Sciences and PACE report no relationships with ineligible companies.

Michele Nichols, PharmD (External Content Reviewer), has no relevant commercial/financial relationships.

Victoria Rosal-Greif, RN, MA (External Content Reviewer), has no relevant commercial/financial relationships.

Accreditation Statements

Jointly provided by Letters & Sciences and Partners for Advancing Clinical Education (PACE)

Letters & Science
Interprofessional Continuing Education

In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and Letters & Sciences. PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


    For Physicians

  • PACE designates this enduring activity for a maximum of 1.0  AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 80% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. In addition, you must complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.


Clinical Pearls & Compelling Evidence for Internists: Integrating Guidelines to Optimize Cardiorenal Outcomes in T2D

Authors: Rajiv Agarwal, MD, MS (Co-Chair); Janet B. McGill, MD, MA; Joseph A. Vassalotti, MD (Co-Chair)Faculty and Disclosures

CME Released: 6/23/2023

Valid for credit through: 6/23/2024, 11:59 PM EST


Learning Feedback Questions

Please answer these questions to complement your learning experience.

  • Print